"Neuregulin-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide factor originally identified by its ability to stimulate the phosphorylation the erbB-2 receptor (RECEPTOR, ERBB-2). It is a ligand for the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Variant forms of NEUREGULIN-1 occur through alternative splicing of its mRNA.
| Descriptor ID |
D020890
|
| MeSH Number(s) |
D12.644.276.860.550.750 D12.776.467.860.550.750 D12.776.631.600.550.750 D23.529.850.550.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuregulin-1".
Below are MeSH descriptors whose meaning is more specific than "Neuregulin-1".
This graph shows the total number of publications written about "Neuregulin-1" by people in this website by year, and whether "Neuregulin-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 0 | 3 |
| 2000 | 8 | 1 | 9 |
| 2001 | 9 | 0 | 9 |
| 2002 | 3 | 2 | 5 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuregulin-1" by people in Profiles.
-
The phase I/II eNRGy trial: Zenocutuzumab in?patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024; 20(16):1057-1067.
-
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. J Thorac Oncol. 2024 01; 19(1):106-118.
-
Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. Genes Dev. 2023 09 01; 37(17-18):818-828.
-
Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling. Circulation. 2021 02 23; 143(8):805-820.
-
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.
-
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 10 01; 78(19):5680-5693.
-
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One. 2018; 13(7):e0200826.
-
NRG1-Fc improves metabolic health via dual hepatic and central action. JCI Insight. 2018 03 08; 3(5).
-
The acceleration of reproductive aging in Nrg1flox/flox ;Cyp19-Cre female mice. Aging Cell. 2017 12; 16(6):1288-1299.
-
Neuregulin-1 type III knockout mice exhibit delayed migration of Schwann cell precursors. Biochem Biophys Res Commun. 2017 04 29; 486(2):506-513.